Radionuclide therapy of bone metastases

Clinical Nuclear Medicine

Volumn , Issue , 2007, Pages 433-442

  Palmedo, H ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892055778     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-540-28026-2_23     Document Type: Chapter

References (61)

1. AkerleyW, Butera J,Wehbe T, Noto R, Stein B, Safran H, Cummings F, Sambandam S, Maynard J, Di Rienzo G, Leone L (2002) A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone. Cancer 94(6):1654-60
2. Anderson PM, Wiseman GA, Dispenzieri A, Arndt CA, Hartmann LC, Smithson WA, Mullan BP, Bruland OS (2002) High-dose samarium-153 ethylene diamine tetramethylene phosphonate: Low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol 20(1):189-96
3. Baud C-A, Boivin G (1980) Periosteocytic remodelling in the vicinity of bone metastases. In: Donath A, Courvoisier B (eds) Bone and tumours.HansHuber, Bern, pp 280-298
4. Baziotis N, Yakoumakis E, Zissimopoulos A, et al. (1998) Sr-89 chloride in the treatment of bone metastases from breast cancer. Oncology 55:377-81
5. Besson JM, Chaouch A (1987) Peripheral and spinal mechanisms of nociception. Physiol Rev 67:67-186
6. Bishayee A, Rao D, Srivastava S, et al. (2000) Marrow-sparing effects of Sn-117m DTPA for radionuclide therapy of bone cancer. J Nucl Med 41:2043-2050
7. Blake GM, ZivanovicMA,McEwan AJ, Ackery DM(1986) Sr-89 therapy: Strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med 12:447-454
8. Blake GM, Zivanovic MA, McEwan AJ, Batty VB, Ackery DM (1987) 89Sr radionuclide therapy: Dosimetry and haematological toxicity in two patients with metastasising prostatic carcinoma. Eur J Nucl Med 13:41-46
9. Blake GM, ZivanovicMA, Blaquiere RM, Fine DR,McEwan AJ, Ackery DM (1988) Strontium-89 therapy: Measurement of absorbed dose to skeletal metastases. J Nucl Med 29:549-557
10. Blake GM, Wood JF, Wood PJ, Zivanovic MA, Lewington VJ (1989a) 89Sr therapy: Strontium plasma clearance in disseminated prostatic carcinoma. Eur J Nucl Med 15:49-54
11. Blake GM, Zivanovic MA, Lewington VJ (1989b) Measurements of the strontium plasma clearance rate in patients receiving Sr89 radionuclide therapy. Eur J Nucl Med 15:780-783
12. Collins C, Eary JF, Donaldson G, et al. (1993) Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: A phase I/II trial. J Nucl Med 34:1839-1844
13. Cserhati P (1987) Metastatic disease in breast cancer. J Clin Oncol 21:1235-41
14. de Klerk JMH, van Dijk A, van het Schip AD, Zonnenberg BA, van Rijk PP (1992) Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases. J Nucl Med 33:646-651
15. Eary JF, Collins C, Stabin M, et al. (1993) Samarium-153-EDTMP biodistribution and dosimetry estimation. J Nucl Med 34:1031-1036
16. Eisenberger MA, Simon R, O'Dwyer PJ, Wittes RE, Friedman MA (1985) A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 3:827-841
17. Foley KM, Arbit E (1989) The management of cancer pain. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: Principles and practice of oncology, 3rd edn. Lippincott, Philadelphia, pp 2064-2087
18. Geldof AA, de Rooij L, Versteegh RT, Newling DW, Teule GJ (1999) Combination 186Re-HEDP and cisplatin supra-additive treatment effects in prostate cancer cells. J Nucl Med 40(4):667-71
19. Gerson BD, Dorfman HD, Norman A, Mantius HJ (1972) Patterns of localization in osteosarcoma. J Bone Joint Surg 54:817-827
20. Han S, Zonnenberg B, De Klerk J, et al. (1999) Re-186 HEDP in breast cancer patientswithmetastatic bone pain. JNuclMed 40:639-642
21. Hauswirth AE, Palmedo H, Dierke-Dzierzon C, et al. (1998) Pain therapy in multiple bone metastases in breast carcinoma. Zentralbl Gyn̈ol 120:83-86
22. Hillner BE, et al. (2000) American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. J Clin Oncol 18:1378-91
23. Holmes RA (1992) [153Sm] EDTMP: A potential therapy for bone cancer pain. Semin Nucl Med 22:41-45
24. Jacobs SC (1983) Spread of prostatic cancer to bone. Urology 21:337-344
25. Kaplan E, Fels IG, Kotlowski BR (1960) Therapy of carcinoma of the prostate metastatic to bone with P-32 labeled condensed phosphate. J Nucl Med 1:1-13
26. Ketring AR (1987) 153Sm-EDTMP and 186Re-HEDP as bone therapeutic radiopharmaceuticals. Nucl Med Biol 14:223-232
27. Kutzner J, DänertW, Schreyer T, GrimmW, Brod KH, Becker M(1981) Yttrium-90 zur Schmerztherapie von Knochenmetastasen. Nuklearmedizin 20:229
28. Laing AH, Ackery DM, Bayly RJ, et al. (1991) Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Br J Rad 64:816-822
29. Lewington VJ (1993) Targeted radionuclide therapy for bone metastases. Eur J Nucl Med 20:66-74
30. Lewington VJ,McEwan AJ, Ackery DM, et al. (1991)A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 27:954-958
31. Maxon HR, Deutsch EA, Thomas SR (1988) Re-186 (Sn)HEDP for treatment of multiple metastatic foci in bone: Human biodistribution and dosimetric studies. Radiology 166:501-507
32. McEwan AJB, Amyotte GA, McGowan DG, MacGillivray JA, Porter AT (1994) Retrospective analysis of the cost effectiveness of treatmentwithMetastron (Strontium-89 chloride) in patients with prostate cancer metastatic to bone. Nucl Med Commun 15:567-71
33. Mense S (1981) Sensitization of group IV muscle receptors to bradykinin by 5-hydroxytryptamine and prostaglandin E2. Brain Res 225:95-105
34. MertensWC, Porter AT, Reid RH, Powe JE (1992) Strontium-89 and low-dose infusion cisplatin for patients with hormone refractory prostate carcinoma metastatic to bone: A preliminary report. J Nucl Med 33(8):1437-43
35. Mundy GR,Martin TJ (1989) Pathophysiology of skeletal complications of cancer. In:Mundy GR,Martin TJ (eds) Physiology and pharmacology of Bone. Springer-Verlag, Berlin Heidelberg New York, pp 641-44
36. Nielsen OS, Munro AJ, Tannock IF (1991) Bone metastases: Pathophysiology and management policy. J Clin Oncol 9(3):509-524
37. Pagliaro LC, Delpassand ES, Williams D, Millikan RE, Tu SM, Logothetis CJ (2003) A phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases. Cancer 97(12):2988-94
38. Palmedo H, Bender H, Schomburg A, Grüwald F, Schoeneich G, Zamora P, Reichmann K, Dierke-Dzierzon C, Mallmann P, Biersack HJ (1996) Schmerztherapie mit Rhenium-186 HEDP bei multiplen Knochenmetastasen. Nuklearmedizin 35 63-67
39. Palmedo H, Grüwald F, Wagner U, et al. (1998) Remission of bone metastases after combined chemotherapy and radionuclide therapywith Re-186 HEDP. ClinNuclMed 23:501-4
40. Palmedo H, Bender H, Dierke-Dzierzon C, Carl UM, Krebs D, Risse J, Biersack HJ (1999) Pain palliation with rhenium-186 HEDP in breast cancer patients with disseminated bonemetastases. Clin Nucl Med 24:643-648
41. Palmedo H, Guhlke S, Bender H, Sartor J, Schoeneich G, Risse J, Grüwald F, Knapp FF, Biersack HJ (2000) Dose escalation study with rhenium-188 HEDP in prostate cancer patients with osseous metastases. Eur J Nucl Med 27:123-130
42. Palmedo H, Manka-Waluch A, Albers P, Schmidt-Wolf IG, Reinhardt M, Ezziddin S, Joe A, Roedel R, Fimmers R, Knapp FF Jr, Guhlke S, Biersack HJ (2003) Repeated bonetargeted therapy for hormone-refractory prostate carcinoma: Randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol 21(15):2869-75
43. Palmedo H, Rockstroh JK, Bangard M, et al. (2006) Therapy with rhenium-186 HEDP in medication-refractory patients with painful multifocal arthritis: Initial results of a prospective study. Radiology (accepted for publication
44. Paterson AHG (1987) Bone metastases in breast cancer, prostate cancer and myeloma. Bone 8 (Suppl 1):17-22
45. Poner A, Mertens W (1991) Strontium 89 in the treatment of metastatic prostate cancer. Can J Oncol 1:11-18
46. Porter AT, McEwan AJB, Powe JE, et al. (1993) Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 25:805-813
47. Quilty PM, Kirk D, Bolger JJ, et al. (1993) A comparison of the palliative effect of strontium 89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 31: 33-40
48. Quirijnen JMSP, Han SH, Zonnenberg BA, et al. (1996) Efficacy of rhenium-186-HEDP in prostate cancer patients with metastatic bone pain. J Nucl Med 37:1511-1515
49. Resch K (1991) Der entzüdliche Gelenkschmerz. In: Zimmermann M, Zeidler H, Ehlers H (eds) Rheuma und Schmerz. Der Schmerz 5(Suppl 1):3-12
50. Robinson RG (1993) Strontium-89 precursor targeted therapy for pain relief of blastic metastatic disease. Cancer 72: 3433-5
51. Schmidt RF (1991) Physiologie und Pathophysiologie der Schmerzentstehung und Schmerzverarbeitung im Bewegungssystem. In: ZimmermannM, Zeidler H, EhlersH(eds) Rheuma und Schmerz. Der Schmerz 5(Suppl 1):13-28
52. Schoeneich G, PalmedoH,Dierke-Dzierzon C,Müler SC, Biersack HJ (1997) Palliative radionuclide therapy of painful bone metastases. Scand J Urol Nephrol 31:445-448
53. Sciuto R, Festa A, Rea S, Pasqualoni R, Bergomi S, Petrilli G, Maini CL (2002) Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: A randomized clinical trial. J Nucl Med 43(1):79-86
54. Serafini AN, Houston SJ, Resche I, et al. (1998) Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: A double blind placebo-controlled trial. J Clin Oncol 16:1574-1581
55. Singh A, Holmes RA, Farhangi M (1989) Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer. J Nucl Med 30:1814-1818
56. Strumpf M (1993) Krebbsschmerz. In: Zenz J, Jurna I (eds) Lehrbuch der Schmerztherapie. Wissenschaftliche Verlagsgesellschaft, Stuttgart, pp 427-436
57. Tian J, Zhang J, Hou Q, et al. (1999)Multicentre trial on the efficacy and toxicity of single dose samarium-153 EDTMP as a palliative treatment for painful skeletal metastases in China. Eur J Nucl Med 26:2-7
58. Tu S,Millikan RE,Mengistu B, et al. (2001) Bone targeted therapy for advanced androgen-independent carcinoma of the prostate: A randomised phase II trial. Lancet 357:336-41
59. Tu SM, Kim J, Pagliaro LC, Vakar-Lopez F, Wong FC, Wen S, General R, Podoloff DA, Lin SH, Logothetis CJ (2005) Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol 23(31):7904-10
60. Willis WD (1985) The pain system. Karger-Verlag, Basel, pp 341-388
61. Zimmermann M (1984) Physiologie von Nozizeption und Schmerz. In: Zimmermann M, Handwerker HO (eds) Schmerz-Konzepte und äztliches Handeln. Springer-Verlag, Berlin, pp 1-43